Präklinische Daten

Daniel E. Furst, Robert Wallis MD, Michael Broder MD and David O. Beenhouwer MD. Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection.
Seminars in Arthritis and Rheumatism 2006;36,3: 159-167
(PubMed)

Catrina AI, AF Klint, Ernestam S, Catrina SB, Makrygiannakis D, Botusan IR, Klareskog L, Ulfgren AK.
Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Arthritis Rheum. 2006 Jan;54(1):76-81.
(PubMed)

Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H.
Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.
J Clin Pharmacol.
2005 Mar;45(3):246-56. 
(PubMed)

Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK.
Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Arthritis Rheum. 2005 Jan;52(1):61-72.
(PubMed)

Zhou H
Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein
J Clin Pharmacol. 2005 May;45(5):490-7
(PubMed)

Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J.
Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept.
Ann Rheum Dis. 2003; 62(6):561-4
(PubMed)

Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK.
Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.
Rheumatology (Oxford). 2002 May;41(5):484-9.
(PubMed)

Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME.
The pharmacokinetics of etanercept in healthy volunteers.
Ann Pharmacother. 2000 Feb;34(2):161-4.
(PubMed)

rheuma-online: TNF-alpha-Blocker: Alle gleich? Oder gibt es Unterschiede?

Copyright © 1997-2021 rheuma-online
rheuma-online Österreich
 
Alle Texte und Beiträge in rheuma-online wurden nach bestem Wissen und Gewissen erstellt. Irrtümer sind jedoch vorbehalten. Alle Angaben sind ohne Gewähr. Jegliche Haftungsansprüche, insbesondere auch solche, die sich aus den Angaben zu Krankheitsbildern, Diagnosen und Therapien ergeben könnten, sind ausgeschlossen.